Dextenza® is an innovative sustained-release corticosteroid insert used to treat ocular inflammation and pain. When the drug received FDA approval for a new indication, the commercial team faced the challenge of educating ophthalmologists and optometrists about this expanded therapeutic application in a competitive market where traditional treatment approaches were deeply entrenched. Healthcare providers needed to understand not only the clinical benefits of the new indication but also how Dextenza's unique sustained-release technology could improve patient outcomes and practice efficiency compared to conventional treatment regimens.

Our team partnered with Dextenza's commercial leadership to develop a comprehensive launch strategy that would establish the new indication among eye care professionals. We created an integrated marketing approach that combined impactful trade show presence, compelling presentation materials, and strategic collateral designed to communicate clinical differentiation at every touchpoint. Our strategy focused on translating complex clinical data into clear value propositions that resonated with busy practitioners, emphasizing how Dextenza's innovative delivery system addressed real-world challenges in their practices while improving the patient experience.

We developed a full suite of launch materials including eye-catching trade show booth designs and graphics that drove booth traffic and facilitated meaningful conversations with qualified healthcare providers. Our team created polished presentation decks and speaker support materials that armed sales representatives and medical affairs teams with persuasive narratives backed by clinical evidence. We designed comprehensive sales collateral including detail aids, leave-behinds, and product brochures that clearly articulated the new indication's benefits, and enhanced the website with dedicated landing pages optimized to educate providers and drive qualified inquiries.